

Measuring Frailty Using Self-Report or Automated Tools to Identify Risk of Cardiovascular Events and Mortality: The Million Veteran Program

Saadia Qazi DO, MPH^{1,2,3,4,*}, Benjamin Seligman MD, PhD^{5,6,*}, Sarah R. Preis ScD, MPH^{3,7,*}, Manas Rane MD^{1,3}, Luc Djousse MD, ScD^{1,3}, David R. Gagnon MD, PhD^{3,7}, Peter W.F. Wilson, MD^{8,9,10}, J. Michael Gaziano MD, MPH^{1,2,3}, Jane A. Driver^{1,4}, Kelly Cho PhD, MPH^{1,3,**}, Ariela R. Orkaby MD, MPH^{1,3,4,**} on behalf of MVP

1. Division of Aging, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
2. Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
3. Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts
4. New England GRECC, VA Boston Health Care System, Boston MA
5. Greater Los Angeles GRECC, VA Greater Los Angeles Health Care System, Los Angeles, CA
6. Division of Geriatric Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
7. Department of Biostatistics, Boston University School of Public Health, Boston, MA
8. Veterans Affairs Atlanta Healthcare System, Decatur, GA
9. Division of Cardiology, Emory University School of Medicine, Atlanta, GA
10. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

Short Title: Association of Frailty with Cardiovascular Events and Mortality

Total Word Count: 3094

Corresponding Author:

Saadia Qazi DO, MPH
Divisions of Cardiovascular Disease and Aging
Brigham and Women's Hospital
Boston VA Medical Center
150 S Huntington Avenue
Boston, MA 02130
Email: sqazi@bwh.harvard.edu

ABSTRACT

Background

Frailty, a syndrome of physiologic vulnerability, increases cardiovascular disease (CVD) risk. Whether in person or automated frailty tools are ideal for identifying CVD risk remains unclear. We calculated three distinct frailty scores and examined their associations with mortality and CVD events in the Million Veteran Program (MVP).

Methods

MVP is a prospective cohort of U.S. Veterans that has enrolled nearly one million Veterans. We included participants aged ≥ 50 years who enrolled from 2011-2018. Frailty was calculated using three tools: two frailty indices (FI) based on the accumulation of deficits theory, the 36-item MVP-FI using self-reported answers to questionnaires, and the 31-item VA-FI developed using claims data. Finally, we calculated the 3-item Study of Osteoporotic Fractures Fried physical frailty score from self-report. The primary outcomes were CVD and all-cause mortality. Multivariable-adjusted Cox proportional hazards models (adjusted for age, sex, smoking, statin use, antihypertensive use, hyperlipidemia, and survey year). Secondary outcomes were myocardial infarction (MI), stroke, and heart failure (HF).

Results

Among 190,688 MVP participants (mean age 69 ± 9 years, 94% male, 85% white), there were 33,233 (17%) all-cause and 10,115 (5%) CVD deaths. Using MVP-FI, 29% were robust, 42% pre-frail, and 29% frail. Frailty prevalence increased by age group, from 27% in 50–59-year-olds to 42% in age ≥ 90 years. Follow-up duration was 6 ± 2 years. Using the MVP-FI, pre-frail and frail Veterans had a higher incidence of both all-cause mortality (pre-frail: HR=1.66, 95% CI: 1.61-1.72; frail: 3.05, 2.95-3.16) and CVD death (pre-frail: 1.76, 1.65-1.88; frail: 3.65, 3.43-3.90), as compared to robust individuals. These findings remained significant among Veterans ≥ 50 years. Findings were similar for CVD events. When frailty was measured using the VA-FI and SOF results were concordant.

Conclusion

Irrespective of frailty measure used, frailty is associated with a higher risk of all-cause mortality and CVD events. Further study of frailty in individuals < 60 years old is warranted.

Key Words: Frailty, Cardiovascular Disease, Risk Stratification

ABBREVIATIONS:

Cardiovascular disease (CVD)

Heart Failure (HF)

Myocardial infarction (MI)

Million Veteran Program (MVP)

Frailty index (FI)

Veterans Administration (VA)

Centers for Medicare and Medicaid Services (CMS)

INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of death among older adults in the United States, responsible for over 750,000 deaths among adults aged ≥ 65 in 2020.¹ Managing this burden is critical to meet *Healthy People 2030* goals for coronary heart disease and stroke deaths.² However, major risk calculators, such as the Framingham Risk Score, Reynold's Risk Calculator, and QRISK-3 have maximum ages of 79, 80, and 84 respectively, while the Pooled Cohort Equations have a maximum age of 75. Risk-stratification of heart disease risk among older adults is challenging, in part due to physiologic aging that includes inflammation, altered metabolism, genomic alterations, and other changes not included in traditional risk calculators, as well as competing risks from other causes of death.³⁻⁵

Frailty may address the challenges of both aging physiology and competing risk when assessing CVD risk in older adults. Defined as the vulnerability to poor health outcomes following a physiologic stressor, frailty is operationalized according to two leading theories:⁶ 1) physical frailty, which treats frailty as a discrete syndrome of weight loss, exhaustion, fatigue, decreased physical activity, and weakness;⁷ and 2) deficit accumulation frailty which considers health-related deficits spanning morbidity, cognition, function, nutrition and mental health.⁸ Both approaches have been associated with major adverse cardiovascular outcomes (MACE) across the spectrum of CVD and may inform prognostication and management of patients.⁹⁻¹² The application of frailty in the management of CVD patients first became standard in aiding risk stratification for transcatheter aortic valve replacement (TAVR) procedures and has subsequently expanded to heart failure prognostication and management and other areas of CV care.^{13,14} Despite the recognition of frailty as a critical tool for prognostication and management in CVD, among the 60 frailty tools developed based on these two theories of frailty, multi-society

guideline recommendations lack specific guidance on which available tool is best.^{15,16} In an effort to address the question of optimal frailty assessment we used the Million Veteran Program (MVP), a large, well-phenotyped cohort of over 900,000 US Veterans. We used both a deficit accumulation and a physical frailty approach to examine the relationship between frailty, mortality, and CVD events.

METHODS

Study Sample

The Million Veteran Program (MVP) is a prospective observational cohort study of US Veterans, which was established to explore the effects of genetics, lifestyle, and military exposures on veteran health.¹⁷ Starting in 2011, veterans who received healthcare through the Veterans Health Association (VHA) were invited to enroll in MVP. Participants completed the MVP Baseline and Lifestyle surveys, provided a blood sample, and allowed access to their VHA health records through the VA's Corporate Data Warehouse (CDW) repository.¹⁸ This study was approved by the VA Central Office Institutional Review Board (IRB) in Washington, DC. A waiver for patient consent was obtained from the VA Boston Healthcare system IRB.

For the present study, we included all participants aged ≥ 50 years who completed both the Baseline and Lifestyle Surveys, during the period of 2011-2018. Participants were excluded if they completed their MVP Lifestyle Survey more than 30 days before or one year after their MVP Baseline Survey, were missing more than 20% of the necessary information to calculate the MVP frailty score, covariates, or date of cardiac event, or died prior to completion of the questionnaire (Supplemental Figure 1).

Frailty Assessments

MVP Frailty Index (MVP-FI)

We used the MVP Baseline and Lifestyle Surveys to develop a deficit accumulation frailty index, the “Million Veteran Program Frailty Index” (MVP-FI), based on a standard procedure using self-reported answers to the questionnaires.¹⁹ This index is composed of 33 deficits covering health status and function, mental health and cognition, and comorbidities. The specific deficits and the point values assigned to the survey responses are listed in Supplemental Table 1. To calculate the MVP-FI, the number of deficits present for an individual were summed and divided by the number of deficits assessed, producing a frailty index value between 0 and 1. If a participant had six or fewer missing responses to the survey items, their MVP-FI was calculated as the number of deficits present divided by the total number of items completed. Individuals with seven or more missing items were excluded. We defined an MVP-FI of 0 to 0.10 as robust, 0.11 to 0.20 as pre-frail, and >0.20 as frail, consistent with prior frailty measures developed within the VA such as the Veterans Affairs Frailty Index (VA-FI).²⁰

Other Frailty Measures

To compare the MVP-FI, which is based solely on self-reported measures, with an automated deficit accumulation frailty measure previously developed using VA medical records, we also calculated the VA-FI.^{11,20,21} The VA-FI uses International Classification of Diseases (ICD) and the Healthcare Common Procedure Coding System (HCPCS) codes from the VA electronic medical records and Medicare claims data to assess 31 deficits including physical health, mental health and cognition, and function. It has been extensively validated in the VA population and associated with all-cause and cardiovascular mortality.^{11,20} We calculated the

VA-FI using clinical claims data from the 36 months preceding completion of the MVP Baseline Survey.

To compare a deficit accumulation frailty index with a physical frailty measure, we operationalized the Study of Osteoporotic Fractures frailty index (SOF) using questionnaire items from the MVP Baseline and Lifestyle Surveys. The original SOF is composed of three items scored as 0 or 1: weight loss, inability to rise from a chair five times without using arms, and reduced energy.²² The MVP surveys contained specific questionnaire items pertaining to weight loss and reduced energy, however, the number of chair stands was not assessed. As a proxy we used the participants' responses to the ADL question "Required assistance with transferring from a bed or chair in the last week." This is similar to other modified versions of the SOF.²³ The specific survey questions and coding are presented in Supplemental Table 2. The SOF scores ranged from 0 to 3. A participant was considered robust if they had a score of 0, pre-frail if they had a score of 1, and frail if they had a score of 2 or 3.

Outcomes

The primary outcomes were CVD and all-cause mortality. Deaths were identified through the National Death Index (NDI). A death was classified as CVD-related if one of the following ICD codes was listed as the primary cause of death in the NDI (ICD-10 codes: I10-I16, I20-I25, I27-I28, I34-I37, I44-I51, I60-I75, I77-I78, I42, I97, I99, R58, G45, R00). Secondly we considered the outcomes of incident ischemic stroke (ICD-9 codes: 433.x1, 434 (excluding 434.x0), 436, 437.0, 437.6; ICD-10 codes: I63.xx9, I63.20, I63.22, I63.50, I63.59, I67.2, I67.6, I67.89), myocardial infarction (MI; ICD-9 codes: 410.x, 411.x, 412.x, 414.x; ICD-10 codes: I20.0, I21.x, I22.x, I24.x, I25.x), and heart failure (ICD-9 code: 428.x; ICD-10 code: I50).²⁴

Secondary outcomes were derived from the VA electronic medical record data linked with Medicare and Medicaid claims.

Clinical Covariates

Information on age, sex, race, and ethnicity was extracted from the MVP Baseline Survey. Smoking status was derived from the MVP Baseline Survey and VHA medical records using a previously published algorithm.²⁵ History of hyperlipidemia (ICD-9 code 272.4; ICD-10 codes: E74.8, E78.5), antihypertensive medication (VA National Formulary classification: CV100, CV150, CV200, CV400, CV490, CV701, CV702, CV704, CV800, CV805, CV806), and statin use were determined using VHA medical records. Medication use was assessed during the 24 months prior to the date of a participant's MVP Baseline Survey date.

Statistical Analysis

Descriptive statistics were calculated using means (standard deviation), medians (interquartile range), or frequency counts and percentages, as appropriate. Spearman correlation coefficients were calculated to examine the correlation between the MVP-FI, VA-FI, and SOF frailty measures. Cox proportional hazards models were used to obtain hazards ratios (HR) and 95% confidence intervals (CI) for the association between each frailty measure and the outcomes. All models were adjusted for age, sex, smoking status, history of hyperlipidemia, antihypertensive treatment, statin use, number of days between the return date of the MVP Baseline Survey and Lifestyle Survey, and the MVP Baseline Survey calendar year. Because the secondary outcomes comprised incidence of CVD events, participants with MI were excluded from models assessing incidence of MI. Similar exclusions were applied for models investigating

incidence of stroke and HF. The analysis was conducted using SAS Enterprise v. 7.1. A p-value of <0.05 was considered statistically significant.

RESULTS

The total study population included 190,688 Veterans as shown in Supplemental Figure 1. Mean age of participants in the overall study was 69 ± 9 years, 11,852 (6%) were female, 161,900 (85%) identified as white and 16,344 (9%) as Black. At baseline, a history of stroke was present in 5% ($n=9,397$), MI in 7% ($n=13,254$) and HF was present in 9% ($n=17,714$) of Veterans. Hyperlipidemia, treatment of hypertension, statin treatment, history of CVD, and history of HF were more common at higher levels of frailty (Table 1).

Overall, 55,487 (29%) of the sample was robust by the MVP-FI, 79,835 (42%) were pre-frail, and 55,366 (29%) were frail. The distribution by VA-FI was similar, with 78,004 (53%) robust, 64,628 (34%) pre-frail, and 48,056 (25%) frail. Using physical frailty as assessed by SOF, 98,434 (53%) were robust, 70,167 (38%) were pre-frail, and 18,091 (10%) were frail. While 86% of included participants were aged ≥ 60 years, 26,248 (14%) were aged 50-59 years, of which 13% were pre-frail and another 13% frail (Table 1). Spearman correlation coefficients between the three frailty indices were as follows: continuous FI scores for MVP FI and SOF = 0.39 ($p<0.0001$), MVP FI and VAFI = 0.61 ($p<0.0001$), VAFI and SOF = 0.25 ($p<0.0001$). The components of each frailty index are described in Figure 2.

Over a mean follow-up of 6 ± 2 years, 17% ($N=33,223$) experienced all-cause mortality, 5% ($N=10,115$) CVD mortality, 1% ($N=2,400$) incident stroke, 2% ($N=3,593$) incident MI, and 9% ($N=15,816$) incident HF events. The associations between frailty and the primary outcomes of all-cause and CVD mortality are shown in Table 2. Using the MVP-FI, for CVD mortality, the

respective HRs for pre-frail and frail were 1.76 (1.65-1.88) and 3.65 (3.43-3.90). For all-cause mortality, the multivariable-adjusted hazard ratio (HR, 95% CI) relative to robust individuals, was 1.66 (1.61-1.72) for pre-frail and 3.05 (2.95-3.16) for frail individuals. Findings were similar for pre-frail and frail individuals using the VA-FI and SOF indices (Table 2).

The associations between frailty and secondary outcomes of incident stroke, MI, and HF are shown in Table 3. The results demonstrate statistically significant associations for the MVP-FI, VA-FI, and SOF with incident CVD events with a dose-response relationship of greater frailty leading to a greater hazard for events for each frailty measure. For example, in multivariable-adjusted models, HR (95%CI) for incident stroke were 1.51 (1.34-1.70) and 2.29 (2.03-2.58), for pre-frail and frail participants using the MVP-FI, with similar patterns for the VA-FI, and SOF.

Figure 1 demonstrates the association of MVP-FI frailty group with all-cause and CVD mortality stratified by age and sex. A nearly 3-fold increase in risk at 50-59 years (HR 2.73; 95%CI 2.36-3.15) was seen in frail participants. The highest risk was among those aged 60-69 years (HR 3.25; 95%CI 3.05-3.46) with a subsequent graded decline by advancing decade. Similar patterns were seen for CVD mortality. When stratified by sex, the hazard of all-cause mortality and CVD mortality was slightly higher in men compared to women for both the pre-frail and frail groups. These patterns remained consistent across frailty indices with some attenuation where sample size was limited.

DISCUSSION

In a contemporary, deeply-phenotyped cohort of US veterans, we demonstrate that both pre-frailty and frailty are significantly associated with all-cause and CVD mortality using three distinct measures of frailty. This was true despite the use of differing parameters extracted from

self-reported and claims-based data for the MVP-FI, VA-FI, and SOF tools. A similar pattern was seen for secondary endpoints such as stroke, MI, and HF. We also identified a graded increase in risk of adverse events with increasing frailty status.

In the Context of Current Literature

Our data demonstrated the burden of frailty was consistent with prior community dwelling populations.²⁶ Prior literature has also demonstrated a significant association between frailty and all-cause mortality. Moreover, a higher number of frailty markers or increasing frailty severity results in a dose-response increase in risk of all-cause mortality across different populations.²⁷⁻³⁰ The risk of mortality associated with frailty in prevalent CVD and the incremental association between frailty and CVD mortality have been previously described.³¹⁻³⁴ In a meta-analysis of patients (N=154,696) with prevalent CVD or at high risk of CVD enrolled in 14 randomized clinical trials, Farooqi et al demonstrated that frailty assessed by the cumulative deficit approach was associated with increased CVD mortality risk after adjusting for baseline comorbidities (HR 2.06, 95% CI 1.76-2.42).³⁵ Veronese et al reported a similar relationship between frailty and CVD mortality in a meta-analysis of 18 cohorts with a nearly four-fold increase in risk of CVD mortality among those participants identified as frail (HR 3.89; 95% CI 2.40-6.34).³⁶ Prior data from VA has demonstrated that among US Veterans aged ≥ 65 years, the VA-FI was predictive of increased risk of all-cause and CVD mortality.³⁷ The present analysis uniquely extends the current literature by demonstrating the consistent prognostic utility of frailty regardless of how it is measured: either deficit accumulation or physical phenotype, using claims data or self-report.

Stratification by age identified that frailty in younger age individuals (aged 50-59), typically not considered for frailty assessments, may portend even greater risk than in older

adults. The prevalence of frailty has been described as ranging from 3.9% to 63% among individuals aged 18-65.³⁸ In our data, 27% of those aged 50-59 were frail using the MVP-FI, and the hazard of dying from a CVD event was nearly three-fold. These findings lay the groundwork for advancing the concept of frailty as a global measure of physiologic age beyond the reliance on numeric age alone, and its potential utility in younger patients for improving CVD risk stratification.

Limited data are available on the relationship between of frailty and incident CVD.^{12,16} Sergi et al showed a 25% higher risk of CVD events comparing pre-frail to non-frail individuals in a population of 1,567 participants aged 65-96 years (HR 1.25; 95% CI 1.05-1.64). Pre-frail resulted in a nearly 80% increase in risk of CVD compared to those who were pre-frail or robust.³⁹ Damluji et al reported a similar association between frailty and CVD events among 3,259 participants of the National Health and Aging Trends Study. Specifically, acute MI (HR 1.95, 95% CI 1.31-2.90) and stroke (HR 1.71, 95% CI 1.34- 2.17), risk was nearly two-fold higher in frail participants.⁴⁰ Both of these studies demonstrated these associations using physical frailty indices. Our study extends these data in a large, contemporary cohort using both deficit accumulation and physical frailty tools that provide similar prognostic information regarding incident CVD risk.

Notably, in addition to considering outcomes such as mortality and atherosclerotic CVD, we expand the literature with our investigation of the association of frailty with HF. Frailty is known to be highly prevalent in patients with HF (36.2-52.8%).¹⁶ Irrespective of type, outcomes are worse among those with prevalent HF who are also frail.⁴¹⁻⁴⁴ Prior to the current study, there has been paucity of literature frailty as a prognostic risk factor for incident HF.

Potential Mechanisms

CVD as a risk factor for frailty and frailty as a predictor of CVD and mortality has been attributed to the bidirectional association between frailty and CVD.¹⁶ The overlapping mechanisms that underlie both frailty and CVD, including inflammation, insulin resistance, and cellular senescence have been described as key players in the development and progression of both CVD and frailty.¹² Systemic inflammation is a shared pathophysiologic mechanism leading to frailty, changes in muscle physiology with aging, and subclinical CVD impacting multiple organ systems.¹² This leads to a cyclical relationship of worsening functional status which then leads to progression of CVD risk factors such as adiposity, metabolic syndrome, and chronic low-grade inflammation.^{12,16}

Clinical Implications and Future Directions

Our data support the use of frailty as a valuable tool for assessing the cardiovascular health of older adults using the most readily available tool. This may be a detailed questionnaire, EHR claims, or self-reported function, and can be tailored to the needs and resources of a particular clinic or health system. For example, in the UK,⁴⁵ frailty has already been included as an automated tool in the electronic health record across all of primary care. Similar strategies can be taken in other healthcare systems to readily identify patients at risk who will benefit from targeted preventive therapies.

The similar performance of different frailty measures as shown in our study is important: different measures will identify different individuals as frail, particularly when comparing physical and deficit accumulation models. This can be a challenge to clinicians given the array of different frailty instruments that are available as well as limited time to undertake an assessment. However, regardless of the variations in frailty assessment tools, the identification of frailty itself portends greater risk of mortality and CVD events. Deficit accumulation frailty indices using

EHR data, such as the VA-FI, present one means of addressing time limitations in frailty assessment. Frailty assessment can then follow up an automated assessment with an in-person evaluation. It is worth noting that frailty tools based on different theories (i.e., physical phenotype and deficit accumulation) by design have poor concordance and a combination of frailty assessment tools may be needed to thoroughly screen patients; however, utilization of any tool(s) at a clinician's disposal can sufficiently risk stratify patients. Supplemental Figure 2 shows a proposed clinic workflow to implement different types of frailty assessment and maximize new information on individuals whose frailty and associated health risks may be missed.

Finally, our findings were robust across age groups. While frailty assessment is often considered a beneficial tool for those aged ≥ 65 , and particularly those ≥ 80 years—exceeding maximum age in most CVD risk calculators—we found that frailty assessment in middle-aged adults may be of clinical utility in risk stratification as well. Further prospective studies are needed to support these findings.

Strengths and Limitations

Our study benefits from a large sample of volunteer participants with extensive follow-up both through a large, integrated health organization linked to the Centers for Medicare and Medicaid Services (CMS). However, these CMS data were available in the older subgroups of our study which may have resulted in underestimation of frailty level in younger groups using the VA-FI.

Our frailty assessment was limited to items covered in survey instruments, which did not include direct physical measures of strength or gait speed nor common blood-based laboratory

tests. The sample included was also predominantly male and white, which may limit generalizability.

CONCLUSION

Frailty, irrespective of how it was measured, is predictive of mortality and CVD, even among those aged 50-59. These findings suggest that clinicians and researchers should use the tool that is most convenient to incorporate frailty into practice.

CLINICAL PERSPECTIVE

- Among Veterans 50 years and older, frailty was associated with a higher risk of CVD and all-cause mortality and adverse events such as incident myocardial infarction, stroke, and heart failure. This association was seen irrespective of type of frailty assessment tool used (i.e., physical phenotype versus deficit accumulation).
- Frailty is a valuable tool for assessing the cardiovascular health of older adults. Among the varying frailty assessment tools such as detailed questionnaire, EHR claims, or self-reported function, the most readily available one can be used based on the needs and resources of a particular clinic or health system.
- Assessment of frailty to evaluate CVD risk may also be useful in younger adults.

SOURCES OF FUNDING:

This work was supported using resources and facilities of the Department of Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457. This work was supported by VA CSRD CDA2 IK2CX001800-01A1. This publication does not represent the views of the Department of Veterans Affairs or the US government.

DISCLOSURES: The authors do not have any relevant financial disclosures.

ACKNOWLEDGEMENTS:

We thank Timothy Treu, MPH for his assistance with the data quality check process.

Support for VA/CMS data provided by the Department of Veterans Affairs, VA Health Services Research and Development Service, VA Information Resource Center (Project Numbers SDR 02-237 and 98-004).

Veterans Health Administration, Center of Excellence for Suicide Prevention. Joint Department of Veterans Affairs and Department of Defense Mortality Data Repository. Data compiled from the National Death Index. https://www.mirecc.va.gov/suicideprevention/documents/VA_DoD-MDR_Flyer.pdf; Extract November 10, 2021.

SUPPLEMENTAL MATERIAL:

Figures

Supplemental Figure 1. Study Sample Selection.

Supplemental Figure 2. Proposed clinic workflow to integrate deficit accumulation and physical frailty assessment.

Tables

Supplemental Table 1. Summary of MVP Baseline and Lifestyle Questionnaire Items Used to Create the MVP Frailty Index.

Supplemental Table 2. Summary of MVP Baseline and Lifestyle Questionnaire Items Used to Create the SOF Index.

Supplemental Table 3. Cox proportional hazard model results for the association between frailty group and mortality, stratified by age group.

Supplemental Table 4. Cox proportional hazard model results for the association between frailty group and mortality among participants who completed their Baseline and Lifestyle Surveys within a 2-year period.

REFERENCES

1. Centers for Disease Control and Prevention. CDC WONDER [Internet]. 2021 [cited 2022 Feb 23]; Available from: <https://wonder.cdc.gov/>
2. Office of Disease Prevention and Health Promotion. Heart Disease and Stroke. Healthy People 2030.

3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. *Cell* 2013;153(6):1194–217.
4. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat Rev Cardiol* 2018;15(9):505–22.
5. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing Risk of Death: An Important Consideration in Studies of Older Adults. *J Am Geriatr Soc* 2010;58(4):783.
6. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in Elderly People. *Lancet* 2013;381(9868):752–62.
7. Fried LP, Tangen CM, Walston J, et al. Frailty in Older Adults: Evidence for a Phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56(3):M146–57.
8. Rockwood K, Mitnitski A. Frailty in Relation to the Accumulation of Deficits. *J Gerontol Ser A* 2007;62(7):722–7.
9. Afilalo J, Lauck S, Kim DH, et al. Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study. *J Am Coll Cardiol* 2017;70(6):689–700.
10. Kim DH, Kim CA, Placide S, Lipsitz LA, Marcantonio ER. Preoperative Frailty Assessment and Outcomes At 6 Months or Later In Older Adults Undergoing Cardiac Surgical Procedures: A Systematic Review. *Ann Intern Med* 2016;165(9):650.
11. Shrauner W, Lord EM, Nguyen XMT, et al. Frailty and cardiovascular mortality in more than 3 million US Veterans. *Eur Heart J* 2022;43(8):818–26.
12. Afilalo J, Alexander KP, Mack MJ, et al. Frailty Assessment in the Cardiovascular Care of Older Adults. *J Am Coll Cardiol* 2014;63(8):747–62.
13. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2022;79(17):e263–421.
14. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2021;143(5):e35–71.
15. Blodgett J, Theou O, Kirkland S, Andreou P, Rockwood K. Frailty in NHANES: Comparing the Frailty Index and Phenotype. *Arch Gerontol Geriatr* 2015;60(3):464–70.
16. Ijaz N, Buta B, Xue Q-L, et al. Interventions for Frailty Among Older Adults With Cardiovascular Disease. *J Am Coll Cardiol* 2022;79(5):482–503.

17. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* 2016;70:214–23.
18. Fihn SD, Francis J, Clancy C, et al. Insights From Advanced Analytics At The Veterans Health Administration. *Health Aff (Millwood)* 2014;33(7):1203–11.
19. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A Standard Procedure for Creating a Frailty Index. *BMC Geriatr* 2008;8(1):24.
20. Orkaby AR, Nussbaum L, Ho Y-L, et al. The Burden of Frailty Among U.S. Veterans and Its Association With Mortality, 2002–2012. *J Gerontol Ser A* 2018;74(8):1257–64.
21. Cheng D, DuMontier C, Yildirim C, et al. Updating and Validating the Veterans Affairs Frailty Index: Transitioning from ICD-9 to ICD-10. *J Gerontol Ser A* 2021;76(7):1318–25.
22. Ensrud KE, Ewing SK, Taylor BC, et al. Comparison of 2 Frailty Indexes for Prediction of Falls, Disability, Fractures, and Death in Older Women. *Arch Intern Med* 2008;168(4):382–9.
23. Orkaby AR, Hshieh TT, Gaziano JM, Djousse L, Driver JA. Comparison of two frailty indices in the physicians’ health study. *Arch Gerontol Geriatr* 2017;71:21–7.
24. Orkaby AR, Driver JA, Ho YL, et al. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. *JAMA* 2020;324(1):68–78.
25. Song RJ, Ho Y-L, Nguyen X-MT, et al. Abstract 18809: Development of an Electronic Health Record-Based Algorithm for Smoking Status Using the Million Veteran Program (MVP) Cohort Survey Response. *Circulation* 2016;134(suppl_1):A18809–A18809.
26. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. *J Am Geriatr Soc* 2012;60(8):1487–92.
27. Peng Y, Zhong G-C, Zhou X, Guan L, Zhou L. Frailty and risks of all-cause and cause-specific death in community-dwelling adults: a systematic review and meta-analysis. *BMC Geriatr* 2022;22(1):725.
28. Shamliyan T, Talley KMC, Ramakrishnan R, Kane RL. Association of frailty with survival: a systematic literature review. *Ageing Res Rev* 2013;12(2):719–36.
29. Vermeiren S, Vella-Azzopardi R, Beckwée D, et al. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. *J Am Med Dir Assoc* 2016;17(12):1163.e1-1163.e17.
30. Ekram ARMS, Woods RL, Britt C, Espinoza S, Ernst ME, Ryan J. The Association between Frailty and All-Cause Mortality in Community-Dwelling Older Individuals: An Umbrella Review. *J Frailty Aging* 2021;10(4):320–6.

31. Man C, Xiang S, Fan Y. Frailty for predicting all-cause mortality in elderly acute coronary syndrome patients: A meta-analysis. *Ageing Res Rev* 2019;52:1–6.
32. Bebb O, Smith FG, Clegg A, Hall M, Gale CP. Frailty and acute coronary syndrome: A structured literature review. *Eur Heart J Acute Cardiovasc Care* 2018;7(2):166–75.
33. Fan J, Yu C, Guo Y, et al. Frailty index and all-cause and cause-specific mortality in Chinese adults: a prospective cohort study. *Lancet Public Health* 2020;5(12):e650–60.
34. Hoogendijk EO, Stenholm S, Ferrucci L, Bandinelli S, Inzitari M, Cesari M. Operationalization of a frailty index among older adults in the InCHIANTI study: predictive ability for all-cause and cardiovascular disease mortality. *Aging Clin Exp Res* 2020;32(6):1025–34.
35. Farooqi MAM, Gerstein H, Yusuf S, Leong DP. Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals. *J Am Heart Assoc* 2020;9(3):e014686.
36. Veronese N, Cereda E, Stubbs B, et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. *Ageing Res Rev*. 2017 May;35:63-73.
37. Orkaby AR, Lunetta KL, Sun FJ, et al. Cross-Sectional Association of Frailty and Arterial Stiffness in Community-Dwelling Older Adults: The Framingham Heart Study. *J Gerontol - Ser Biol Sci Med Sci* 2019;74(3):373–9.
38. Loecker C, Schmaderer M, Zimmerman L. Frailty in Young and Middle-Aged Adults: An Integrative Review. *J Frailty Aging* 2021;10(4):327–33.
39. Sergi G, Veronese N, Fontana L, et al. Pre-frailty and risk of cardiovascular disease in elderly men and women: the Pro.V.A. study. *J Am Coll Cardiol* 2015;65(10):976–83.
40. Damluji AA, Chung S-E, Xue Q-L, et al. Frailty and cardiovascular outcomes in the National Health and Aging Trends Study. *Eur Heart J* 2021;42(37):3856–65.
41. Pandey A, Segar MW, Singh S, et al. Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. *Circulation* 2022;146(2):80–90.
42. Dewan P, Jackson A, Jhund PS, et al. The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE. *Eur J Heart Fail* 2020;22(11):2123–33.
43. Butt JH, Dewan P, Merkely B, et al. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. *Ann Intern Med* 2022;175(6):820–30.

44. McKechnie DG, Papacosta AO, Lennon LT, Ramsay SE, Whincup PH, Wannamethee SG. Frailty and incident heart failure in older men: the British Regional Heart Study. *Open Heart* 2021;8(1):e001571.
45. Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, Mohammed MA, Parry J, Marshall T. Development and validation of an electronic frailty index using routine primary care electronic health record data. *Age Ageing*. 2016 May;45(3):353-60.

Table 1. Baseline characteristics and outcomes of 190,688 participants of the Million Veteran Program.

	MVP-FI Frailty Status			Total (190,688)
	Robust (N=55,487)	Pre-Frail (N=79,835)	Frail (N=55,366)	
MVP Frailty Index Score				
Mean ± SD	0.064±0.026	0.149±0.028	0.282±0.078	0.163±0.098
Median (25 th , 75 th percentile)	0.068 (0.045, 0.083)	0.148 (0.121, 0.174)	0.258 (0.227, 0.313)	0.148 (0.091, 0.212)
Minimum, maximum	0.000, 0.100	0.102, 0.200	0.202, 0.914	0.000, 0.914
SOF Index				
Robust (0)	39338 (72.12)	43545 (55.59)	15551 (28.89)	98434 (52.73)
Pre-frail (1)	14354 (26.32)	29467 (37.62)	26346 (48.95)	70167 (37.58)
Frail (2,3)	854 (1.57)	5314 (6.78)	11923 (22.15)	18091 (9.69)
VA-FI				
Robust	41051 (73.98)	30107 (37.71)	6846 (12.36)	78004 (40.91)
Pre-frail	11790 (21.25)	33626 (42.12)	19212 (34.7)	64628 (33.89)
Frail	2646 (4.77)	16102 (20.17)	29308 (52.94)	48056 (25.2)
Years of Follow-up, Mean ± SD	6.4±2.0	6.2±2.2	5.7±2.4	6.1±2.2
Age (years), Mean ± SD	68±9	70±9	70±9	69±9
Age category, n (%)				
50-59 years	9302 (16.76)	10042 (12.58)	7304 (13.19)	26648 (13.97)
60-69 years	24276 (43.75)	33105 (41.47)	23086 (41.7)	80467 (42.2)
70-79 years	15974 (28.79)	23958 (30.01)	15463 (27.93)	55395 (29.05)
80-89 years	5372 (9.68)	11143 (13.96)	7981 (14.41)	24496 (12.85)
≥90 years	563 (1.01)	1587 (1.99)	1532 (2.77)	3682 (1.93)
Female sex, n (%)	3330 (6.00)	4725 (5.92)	3797 (6.86)	11852 (6.22)
Race, n (%)				
White	48552 (87.5)	68341 (85.6)	45007 (81.29)	161900 (84.9)
Black/African-American	4039 (7.28)	6752 (8.46)	5543 (10.01)	16334 (8.57)
Asian	405 (0.73)	486 (0.61)	336 (0.61)	1227 (0.64)
Native Hawaiian/Pacific Islander	53 (0.10)	97 (0.12)	87 (0.16)	237 (0.12)
American Indian/Alaska Native	203 (0.37)	441 (0.55)	524 (0.95)	1168 (0.61)
Hispanic/Latino ethnicity	2811 (5.08)	4081 (5.13)	3545 (6.42)	10437 (5.49)
Multi-race	1405 (2.53)	2482 (3.11)	2643 (4.77)	6530 (3.42)
Other	725 (1.31)	1102 (1.38)	1128 (2.04)	2955 (1.55)
Unknown	105 (0.19)	134 (0.17)	98 (0.18)	337 (0.18)
Smoking status, n (%)				
Never smoker	19705 (35.51)	21931 (27.47)	12606 (22.77)	54242 (28.45)
Former smoker	27384 (49.35)	43183 (54.09)	30234 (54.61)	100801 (52.86)
Current smoker	8398 (15.14)	14721 (18.44)	12526 (22.62)	35645 (18.69)
Hypercholesterolemia, n (%)	34424 (62.04)	57808 (72.41)	44203 (79.84)	136435 (71.55)
Statin treatment*, n (%)	21247 (38.29)	42432 (53.15)	36534 (65.99)	100213 (52.55)
Antihypertensive treatment*, n (%)	24917 (44.91)	53442 (66.94)	44789 (80.9)	123148 (64.58)
Baseline survey year, n (%)				
2011-2012	11869 (21.39)	18291 (22.91)	12867 (23.22)	43027 (22.56)
2013-2014	18516 (33.37)	26165 (32.77)	18014 (32.51)	62695 (32.87)
2015-2016	14370 (25.9)	20690 (25.91)	14821 (26.75)	49881 (26.15)
2017-2018	10735 (19.35)	14702 (18.41)	9703 (17.51)	35140 (18.42)
History of stroke at baseline, n (%)	767 (1.38)	3118 (3.91)	5512 (9.96)	9397 (4.93)
History of MI at baseline, n (%)	1104 (1.99)	4653 (5.83)	7497 (13.54)	13254 (6.95)
History of CHF at baseline, n (%)	1269 (2.29)	5674 (7.11)	10771 (19.45)	17714 (9.29)

<i>Outcomes</i>				
All-cause mortality, n (%)	4717 (8.50)	13060 (16.36)	15446 (27.9)	33223 (17.42)
Cardiovascular mortality, n (%)	1217 (2.19)	3775 (4.73)	5123 (9.25)	10115 (5.3)
Incident stroke, n (%)	405 (0.74)	997 (1.30)	998 (2.00)	2400 (1.32)
Incident MI, n (%)	531 (0.98)	1482 (1.97)	1580 (3.30)	3593 (2.02)
Incident CHF, n (%)	2344 (4.32)	6587 (8.88)	6885 (15.44)	15816 (9.14)

Abbreviations: SOF, Study of Osteoporotic Fractures FI, frailty index; MI, myocardial infarction; CHF, congestive heart failure.

Table 2. Cox proportional hazard models for the association between frailty group and mortality.

Outcome	Frailty Definition	No. Events	Total No.	HR (95% CI)*	P-value	c**	
All-cause mortality	MVP-FI	Robust	4,717	55,487	1.00 (Referent)	---	0.739
		Pre-frail	13,060	79,835	1.66 (1.61-1.72)	<0.0001	
		Frail	15,446	55,366	3.05 (2.95-3.16)	<0.0001	
	VA-FI	Robust	7,196	78,004	1.00 (Referent)	---	0.741
		Pre-frail	10,931	64,628	1.59 (1.54-1.64)	<0.0001	
		Frail	15,096	48,056	2.94 (2.85-3.04)	<0.0001	
	SOF Index	Robust	13,574	98,434	1.00 (Referent)	---	0.730
		Pre-frail	13,538	70,167	1.57 (1.54-1.61)	<0.0001	
		Frail	5,154	18,091	2.60 (2.52-2.69)	<0.0001	
CVD death	MVP-FI	Robust	1,217	55,487	1.00 (Referent)	---	0.779
		Pre-frail	3,775	79,835	1.76 (1.65-1.88)	<0.0001	
		Frail	5,123	55,366	3.65 (3.43-3.90)	<0.0001	
	VA-FI	Robust	1,793	78,004	1.00 (Referent)	---	0.781
		Pre-frail	3,162	64,628	1.70 (1.60-1.81)	<0.0001	
		Frail	5,160	48,056	3.52 (3.33-3.73)	<0.0001	
	SOF Index	Robust	4,142	98,434	1.00 (Referent)	---	0.762
		Pre-frail	4,094	70,167	1.58 (1.51-1.65)	<0.0001	
		Frail	1,569	18,091	2.63 (2.48-2.79)	<0.0001	

Abbreviations: SOF, Study of Osteoporotic Fractures FI, frailty index; CVD, cardiovascular disease.

*Adjusted for age, sex, smoking status, statin use, antihypertensive treatment, history of hyperlipidemia, days between MVP baseline and lifestyle surveys, and MVP baseline survey year.

** Harrell's c-statistic

Table 3. Cox proportional hazard models for the association between frailty group and CVD outcomes.

Outcome	Frailty Definition	No. Events	Total No.	HR (95% CI)*	P-value	c**	
MI	MVP-FI	Robust	531	54,383	1.00 (Referent)	---	0.720
		Pre-frail	1,482	75,182	1.69 (1.53-1.87)	<0.0001	
		Frail	1,580	47,869	2.67 (2.41-2.95)	<0.0001	
	VA-FI	Robust	976	76,487	1.00 (Referent)	---	0.716
		Pre-frail	1,302	60,369	1.43 (1.31-1.56)	<0.0001	
		Frail	1,315	40,578	2.22 (2.03-2.43)	<0.0001	
	SOF Index	Robust	1,573	93,093	1.00 (Referent)	---	0.706
		Pre-frail	1,483	64,619	1.29 (1.20-1.38)	<0.0001	
		Frail	446	16,043	1.54 (1.39-1.72)	<0.0001	
Stroke	MVP-FI	Robust	405	54,720	1.00 (Referent)	---	0.710
		Pre-frail	997	76,717	1.51 (1.34-1.70)	<0.0001	
		Frail	998	49,854	2.29 (2.03-2.58)	<0.0001	
	VA-FI	Robust	670	76,972	1.00 (Referent)	---	0.707
		Pre-frail	893	61,788	1.45 (1.30-1.60)	<0.0001	
		Frail	837	42,531	2.06 (1.85-2.30)	<0.0001	
	SOF Index	Robust	1,052	94,817	1.00 (Referent)	---	0.701
		Pre-frail	980	66,251	1.33 (1.22-1.45)	<0.0001	
		Frail	315	16,533	1.75 (1.54-1.99)	<0.0001	
CHF	MVP-FI	Robust	2,344	54,218	1.00 (Referent)	---	0.710
		Pre-frail	6,587	74,161	1.69 (1.61-1.77)	<0.0001	
		Frail	6,885	44,595	2.95 (2.81-3.09)	<0.0001	
	VA-FI	Robust	3,600	76,847	1.00 (Referent)	---	0.715
		Pre-frail	5,968	60,156	1.72 (1.65-1.80)	<0.0001	
		Frail	6,248	35,971	3.07 (2.94-3.21)	<0.0001	
	SOF Index	Robust	6,958	92,322	1.00 (Referent)	---	0.692
		Pre-frail	6,402	62,317	1.39 (1.34-1.44)	<0.0001	
		Frail	2,071	14,858	1.99 (1.89-2.09)	<0.0001	

Abbreviations: CVD, cardiovascular disease; SOF, Study of Osteoporotic Fractures FI, frailty index; MI, myocardial infarction; CHF, congestive heart failure.

*Adjusted for age, sex, smoking status, statin use, antihypertensive treatment, history of hyperlipidemia, days between MVP baseline and lifestyle surveys, and MVP baseline survey year.

** Harrell's c-statistic

Table 4. Cox proportional hazard models for the association between frailty group and mortality, stratified by sex.

Sex	Frailty Definition		Total No.	All-Cause Mortality			CVD Death				
				No. Events	HR (95% CI)*	P-value	c**	No. Events	HR (95% CI)*	P-value	c**
Female	MVP-FI	Robust	3,330	102	1.00 (Referent)	---	0.790	21	1.00 (Referent)	---	0.853
		Pre-frail	4,725	279	1.35 (1.07-1.7)	0.01		61	1.27 (0.77-2.1)	0.35	
		Frail	3,797	514	2.64 (2.11-3.3)	<.0001		144	3.03 (1.88-4.86)	<.0001	
	VA-FI	Robust	5,114	167	1.00 (Referent)	---	0.794	39	1.00 (Referent)	---	0.849
		Pre-frail	3,887	262	1.46 (1.2-1.79)	0.0002		58	1.16 (0.76-1.76)	0.49	
		Frail	2,851	466	2.79 (2.3-3.39)	<.0001		129	2.5 (1.69-3.68)	<.0001	
	SOF Index	Robust	5,346	312	1.00 (Referent)	---	0.783	84	1.00 (Referent)	---	0.840
		Pre-frail	4,878	399	1.49 (1.29-1.74)	<.0001		97	1.39 (1.04-1.87)	0.03	
		Frail	1,409	163	2.34 (1.93-2.83)	<.0001		40	2.29 (1.56-3.37)	<.0001	
Male	MVP-FI	Robust	52,157	4,615	1.00 (Referent)	---	0.732	1,196	1.00 (Referent)	---	0.772
		Pre-frail	75,110	12,781	1.67 (1.61-1.73)	<.0001		3,714	1.77 (1.66-1.89)	<.0001	
		Frail	51,569	14,932	3.06 (2.96-3.17)	<.0001		4,979	3.67 (3.43-3.91)	<.0001	
	VA-FI	Robust	72,890	7,029	1.00 (Referent)	---	0.735	1,754	1.00 (Referent)	---	0.774
		Pre-frail	60,741	10,669	1.59 (1.54-1.64)	<.0001		3,104	1.72 (1.62-1.82)	<.0001	
		Frail	45,205	14,630	2.95 (2.86-3.04)	<.0001		5,031	3.55 (3.35-3.76)	<.0001	
	SOF Index	Robust	93,088	13,262	1.00 (Referent)	---	0.723	4,058	1.00 (Referent)	---	0.754
		Pre-frail	65,289	13,139	1.58 (1.54-1.62)	<.0001		3,997	1.58 (1.52-1.65)	<.0001	
		Frail	16,682	4,991	2.61 (2.53-2.7)	<.0001		1,529	2.64 (2.49-2.8)	<.0001	

Abbreviations: SOF, Study of Osteoporotic Fractures FI, frailty index; CVD, cardiovascular disease.

*Adjusted for age, smoking status, statin use, antihypertensive treatment, history of hyperlipidemia, days between MVP baseline and lifestyle surveys, and MVP baseline survey year.

** Harrell's c-statistic

FIGURE LEGEND

Figure 1. Hazards ratios (HR) for the association between frailty group and *all-cause mortality* (upper panel) and *CVD mortality* (lower panel), stratified by 10-year age group.

Figure 2. Graphical Overview of frailty indices (MVP-FI, VA-FI, and SOF Index). Percentages shown indicate the proportion of total deficits for each frailty index attributed to each domain (health status/function, comorbidities, mood, and cognition).

Figure 1.




Figure 2.

